Compare · RXST vs STAA
RXST vs STAA
Side-by-side comparison of RxSight Inc. (RXST) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RXST and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- STAA is the larger of the two at $1.12B, about 5.7x RXST ($194.2M).
- Over the past year, RXST is down 45.3% and STAA is down 15.0% - STAA leads by 30.3 points.
- STAA has been more active in the news (4 items in the past 4 weeks vs 1 for RXST).
- Both have 25 recent analyst ratings on file.
- Company
- RxSight Inc.
- STAAR Surgical Company
- Price
- $4.51-3.22%
- $21.27-4.45%
- Market cap
- $194.2M
- $1.12B
- 1M return
- -15.15%
- +0.14%
- 1Y return
- -45.30%
- -15.00%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 1
- 4
- Recent ratings
- 25
- 25
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest RXST
- K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
- Officer Weinberg Eric exercised 35,168 shares at a strike of $4.34, increasing direct ownership by 18% to 235,516 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Wilterding Mark
- SEC Form 4 filed by Officer Weinberg Eric
- SEC Form 4 filed by Chief Medical Officer Kurtz Ronald M Md
- SEC Form 4 filed by Chief Operating Officer Goldshleger Ilya
- Amendment: SEC Form SC TO-I/A filed by RxSight Inc.
- Chief Medical Officer Kurtz Ronald M Md converted options into 13,425 shares and sold $35,496 worth of shares (5,100 units at $6.96), increasing direct ownership by 13% to 71,775 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Wilterding Mark converted options into 20,441 shares and sold $54,044 worth of shares (7,765 units at $6.96), increasing direct ownership by 102% to 25,049 units (SEC Form 4) (tax withholding)
- Chief Operating Officer Goldshleger Ilya converted options into 5,370 shares and sold $14,205 worth of shares (2,041 units at $6.96), increasing direct ownership by 4% to 81,509 units (SEC Form 4) (tax withholding)
Latest STAA
- STAAR Surgical Names Andrew Pilon as Vice President of Business Development
- Amendment: STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical upgraded by Stifel with a new price target
- STAAR Surgical Board Approves $50 Million Share Repurchase Authorization
- STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction
- STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer
- Chief Development Officer Michna Magda exercised 6,599 shares at a strike of $4.36 and covered exercise/tax liability with 3,356 shares, increasing direct ownership by 9% to 41,343 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 5,233 shares and covered exercise/tax liability with 2,662 shares, increasing direct ownership by 7% to 38,910 units (SEC Form 4)
- President and CEO Foust Warren converted options into 10,997 shares and covered exercise/tax liability with 5,595 shares, increasing direct ownership by 11% to 95,816 units (SEC Form 4)
- SEC Form 10-Q filed by STAAR Surgical Company